Crescita Reports Third Quarter 2023 Results
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”) announced today that the Toronto Stock Exchange (the “TSX”) has approved the Company’s proposed normal course issuer bid (“NCIB”) to purchase up to a maximum of 1,821,616 common shares (“Common Shares”) for cancellation, representing approximately 10% of its public float as of August 18, 2023, as appropriate opportunities arise from time to time. As of August 27, 2023, the Company had 20,374,153 issued and outstanding Common Shares.
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 20, 2023. The detailed results of the votes received by proxy are as follows:
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the first quarter ended March 31, 2023 (“Q1-F2023”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted.
Crescita Reports Q4 and Fiscal 2022 Results
Crescita Reports Third Quarter 2022 Results
Crescita Reports Second Quarter 2022 Results
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its 2022 Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Québec.
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the first quarter ended March 31, 2022 (“Q1-F2022”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted.
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”) today announced that its CEO, Serge Verreault, will be presenting at the 2022 Bloom Burton & Co. Healthcare Investor Conference, to be held on May 2 and 3, 2022, featuring approximately 60 of Canada's most promising publicly-traded and venture-backed healthcare companies.